Navigation Links
Azur Pharma and Elan Corporation (NYSE: ELN) Sign Agreement to Develop a Once-Daily Clozapine
Date:11/10/2008

DUBLIN, November 10 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced that it has entered into an agreement to develop and commercialise once-daily formulations of clozapine using Elan Corporation plc's ("Elan")(NYSE:ELN) proprietary drug delivery technologies, including its NanoCrystal(r) technology.

Clozapine is currently marketed in immediate release presentations, including Azur's proprietary orally disintegrating tablet brand, FazaClo(r). Clozapine is indicated for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia, and for reducing the risk of recurrent suicidal behaviour in patients with schizophrenia or schizoaffective disorders. Formulation development activities have been underway since 2007 under a preliminary agreement with Elan, and the companies have now elected to progress to a full development programme.

Seamus Mulligan, Chairman and Chief Executive of Azur, commented, "We are pleased to collaborate with Elan to apply their unique patented drug delivery technologies to this important drug. We have already made significant progress under our preliminary agreement. This represents a very significant commercial opportunity that will leverage Azur's existing infrastructure and knowledge of the clozapine market, and build on Azur's other FazaClo line extension programmes."

Under the terms of the agreement, Azur will be responsible for the clinical development programme, the regulatory approval process, and the commercialisation of the product in the US, with an option to expand its rights to countries outside the US. Elan will develop the formulation and manufacture the product. Elan will receive payments upon the achi
'/>"/>

SOURCE Azur Pharma Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
2. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
3. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
4. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
7. Critical Pharmaceuticals Raise GBP650K
8. WellSpring Pharmaceutical Corp. Announces Hire of Wayne Miller as Vice President, Sales & Marketing, Consumer Brands
9. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
10. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
11. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... 2011 Physicians and scientists from Reproductive Medicine ... results of their groundbreaking research study entitled ... Potential While Blastocyst Biopsy Does Not: A Novel ... Embryos.   The study, led by Richard T. ...
... Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. ... Annual BIO Investor Forum.  Hosted by the Biotechnology Industry Organization ... and emerging public companies. The meeting will take place October ... Chain will be presenting on October 26th at 1:30 p.m. ...
... Oct. 19, 2011 Process automation specialist Endress+Hauser has ... that develops, produces and distributes sensors, hardware and software ... strengthen its position in the area of biotechnology through ... role in the future, not only in the life ...
Cached Biology Technology:Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 2Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 3Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 2Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 3
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... of researchers has developed a new nanoscale agent for ... for assessing the function and properties of the GI ... and treatment of gut diseases. , Illnesses ... and inflammatory bowel disease all occur in the intestine ... with diseases such as diabetes and Parkinson,s. , ...
(Date:7/24/2014)... at NJIT this week for an all-day public forum ... Protection Agency (EPA) to dredge toxic sediment from an ... EPA has called the plan, which proposes removing 4.3 ... of the riverbed, one of the largest cleanups in ... and disposed off-site. , "We need to ensure the ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... COLUMBUS, Ohio Retroviruses such as HIV and HTLV-1 don,t ... their own DNA into the cell,s DNA, and from this ... But that infection might be much less troublesome and much ... response to the virus during its first few days in ...
... major 7.0-magnitude earthquake struck the Haitian capital of Port-au-Prince ... quake was followed by several aftershocks with magnitudes over ... maps suddenly out of date, causing additional challenges to ... can help rescue efforts by providing updated views of ...
... The University of Plymouth is to provide 500,000 funding ... of research in partnership with the University, it was announced ... epidemiology in oral health, including the review of published evidence ... of dental research data. The second will look ...
Cached Biology News:Early immune response needed for hit-and-hide cancer viruses 2First satellite map of Haiti earthquake 2First satellite map of Haiti earthquake 3University of Plymouth invests in dental research 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: